345 related articles for article (PubMed ID: 28828581)
1. Optimizing tumor immune response through combination of radiation and immunotherapy.
El Chediak A; Shamseddine A; Bodgi L; Obeid JP; Geara F; Zeidan YH
Med Oncol; 2017 Aug; 34(9):165. PubMed ID: 28828581
[TBL] [Abstract][Full Text] [Related]
2. Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.
Ishihara D; Pop L; Takeshima T; Iyengar P; Hannan R
Cancer Immunol Immunother; 2017 Mar; 66(3):281-298. PubMed ID: 27743027
[TBL] [Abstract][Full Text] [Related]
3. Immune modulation and stereotactic radiation: improving local and abscopal responses.
Zeng J; Harris TJ; Lim M; Drake CG; Tran PT
Biomed Res Int; 2013; 2013():658126. PubMed ID: 24324970
[TBL] [Abstract][Full Text] [Related]
4. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges.
Hodge JW; Guha C; Neefjes J; Gulley JL
Oncology (Williston Park); 2008 Aug; 22(9):1064-70; discussion 1075, 1080-1, 1084. PubMed ID: 18777956
[TBL] [Abstract][Full Text] [Related]
5. Mathematical modeling of the synergistic interplay of radiotherapy and immunotherapy in anti-cancer treatments.
Castorina P; Castiglione F; Ferini G; Forte S; Martorana E; Giuffrida D
Front Immunol; 2024; 15():1373738. PubMed ID: 38779678
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy.
Lee S; Son B; Park G; Kim H; Kang H; Jeon J; Youn H; Youn B
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30227629
[TBL] [Abstract][Full Text] [Related]
7. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation.
Demaria S; Pilones KA; Vanpouille-Box C; Golden EB; Formenti SC
Radiat Res; 2014 Aug; 182(2):170-81. PubMed ID: 24937779
[TBL] [Abstract][Full Text] [Related]
8. The Promise of Combining Radiation Therapy With Immunotherapy.
Jagodinsky JC; Harari PM; Morris ZS
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):6-16. PubMed ID: 32335187
[TBL] [Abstract][Full Text] [Related]
9. Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy.
Xuan L; Bai C; Ju Z; Luo J; Guan H; Zhou PK; Huang R
Cytokine Growth Factor Rev; 2024 Feb; 75():1-11. PubMed ID: 38061920
[TBL] [Abstract][Full Text] [Related]
10. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer.
Kwilas AR; Donahue RN; Bernstein MB; Hodge JW
Front Oncol; 2012; 2():104. PubMed ID: 22973551
[TBL] [Abstract][Full Text] [Related]
11. The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer.
Sacchi de Camargo Correia G; Zhao Y; Manochakian R; Lou Y
Front Oncol; 2024; 14():1336546. PubMed ID: 38476371
[TBL] [Abstract][Full Text] [Related]
12. Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy.
Morel D; Robert C; Paragios N; Grégoire V; Deutsch E
Clin Cancer Res; 2024 Jun; 30(11):2317-2332. PubMed ID: 38477824
[TBL] [Abstract][Full Text] [Related]
13. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives.
Wisdom AJ; Barker CA; Chang JY; Demaria S; Formenti S; Grassberger C; Gregucci F; Hoppe BS; Kirsch DG; Marciscano AE; Mayadev J; Mouw KW; Palta M; Wu CC; Jabbour SK; Schoenfeld JD
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1404-1421. PubMed ID: 38184173
[TBL] [Abstract][Full Text] [Related]
14. Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.
Cogels MM; Rouas R; Ghanem GE; Martinive P; Awada A; Van Gestel D; Krayem M
Front Oncol; 2021; 11():784947. PubMed ID: 34869042
[TBL] [Abstract][Full Text] [Related]
15. The Immunoregulatory Potential of Particle Radiation in Cancer Therapy.
Ebner DK; Tinganelli W; Helm A; Bisio A; Yamada S; Kamada T; Shimokawa T; Durante M
Front Immunol; 2017; 8():99. PubMed ID: 28220126
[TBL] [Abstract][Full Text] [Related]
16. Predictors of clinical response to immunotherapy with or without radiotherapy.
Hiniker SM; Maecker HT; Knox SJ
J Radiat Oncol; 2015; 4():339-345. PubMed ID: 26709361
[TBL] [Abstract][Full Text] [Related]
17. Should we be combining local tumor therapies with immunotherapies as standard?
Baues C; Schlaak M; von Bergwelt-Baildon M; Theurich S
Future Oncol; 2017 Aug; 13(18):1573-1575. PubMed ID: 28829189
[No Abstract] [Full Text] [Related]
18. Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.
Kumar SS; Higgins KA; McGarry RC
Front Oncol; 2017; 7():197. PubMed ID: 28929083
[TBL] [Abstract][Full Text] [Related]
19. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Day D; Monjazeb AM; Sharon E; Ivy SP; Rubin EH; Rosner GL; Butler MO
Clin Cancer Res; 2017 Sep; 23(17):4980-4991. PubMed ID: 28864726
[TBL] [Abstract][Full Text] [Related]
20. Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Aboudaram A; Modesto A; Chaltiel L; Gomez-Roca C; Boulinguez S; Sibaud V; Delord JP; Chira C; Delannes M; Moyal E; Meyer N
Melanoma Res; 2017 Oct; 27(5):485-491. PubMed ID: 28858075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
